Jazz Pharmaceuticals plc · Drugmakers

JAZZ

Moderate riskNext report: Around Jan 11, 2027 (est.)

View price ↗

The short version

A company still losing money with growing sales.

Going well

Sales up 16% in the latest quarter vs a year ago

Watch out for

Losing money
Debt above equity: 1.24x

Money moves

Insiders sold $1.9M in the last 30 days, all through pre-planned sales
Institutions cut 1% from their holdings in the quarter ending June 2026 (368 bought, 244 sold)

Facts from SEC filings, not a recommendation.

What the price means

Price as of Oct 26

$205.64-3.9% that day

Company value: $13.3B; Share price times all shares
Price vs profit (P/E): 14.1x; You pay about $14 for each $1 of yearly profit
Price vs sales: 2.9x; Company value is 2.9 times a year of sales
Cash vs value: 12%; Cash as a share of company value
Debt vs value: 40%; Debt as a share of company value

From JAZZ's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.

The business over time

Last 12 quarters, from SEC filings

Sales, Jun '26

$1.2B+16% vs a year earlier

Sep '23Tap a barJun '26

Last 12 months: $4.6B, up 13% from the 12 months before. Over 5 years, sales grew about 13% a year.

What the price assumes

Your guesses, our math

Move the sliders to your own view of JAZZ. Starting points are the company's recent numbers.

Sales growth+13% a yearRecently: +13% a yearProfit margin20%Last 12 months: 20.4%P/E at the end14xToday: 14.1x. Many steady companies trade at 12x to 25xShare count change-1% a yearBelow zero means buybacks; above zero means new shares (dilution)

Sales in 5 years$8.5B

Profit in 5 years$1.7B

Price these guesses point to$384.51+87% vs $205.64 todayAbout +13% a year, before dividends

What today's price needs: with a 20% margin and a 14x P/E, sales could shrink about 0.3% a year for 5 years and still match today's price.

Simple math on your guesses, not a forecast or a price target. Real results depend on many things these sliders leave out.

Price

Price chart by TradingView.

Business quality

The checklist Warren Buffett-style investors use. Annual numbers for 2025.

2/6Weak

MissReturn on equity 15%+Earns a lot on the money owners have in the business.-8.5%
MissDebt under half of equityNot relying on borrowed money.1.24x equity
MissNet margin 10%+Keeps at least 10 cents of profit from each dollar of sales.-8.3%
MissProfitable every yearSteady profits, not one good year.7 of 10 years
PassFree cash flow positiveBrings in more cash than it spends to run and grow.$1.3B
PassShare count not growingNot diluting owners. Falling means buybacks.-2.5% in 3 years

Revenue: $4.3B; +4.9% vs prior year
5-year growth: +12.5%/yr; revenue, per year
Total debt: $5.4B; 1.24x equity
Current ratio: 1.86x; short-term assets / bills due

From annual reports filed with the SEC. Not in this company's SEC data, so not scored: gross margin 40%+. A checklist is a starting point for research, not a verdict.

Latest quarter

Quarter ended Jun 30, 2026

Reported Oct 26After close4:03 pm ET

From the press release

The expected IPR&D charge is not tax deductible and is estimated to represent an unfavorable impact of approximately $11.00 to both GAAP earnings per share (“EPS”) and non-GAAP adjusted EPS for the third quarter of 2026.

The numbers below are the quarter before. The new quarter's full numbers come with the 10-Q. Read the press release ↗

Revenue: $1.2B; +15.5% YoY
EPS: $2.78; vs -$11.74
Op. margin: 20.5%; +86.1 pts
Free cash flow: $397.6M
Share count: +13.4%; vs a year ago

Insider rating

Last 90 days

44Mixed

Pre-planned sales of $1.9M (weaker signal)

50 is neutral. Buying by more insiders, top executives and bigger stakes raises it. Selling lowers it; pre-planned sales count less.

Weekly insider trend

13 weeks agoBoughtSoldThis week

Filing buzz

Last 7 days vs normal

17/ 100

This week: 1
Normal week: 5.0
vs normal: 0.2x

SEC filings of any kind. 50 means a normal week.

Institutional ownership

Steady-1.0%

Institutions cut 1.0% from their holdings. 368 bought, 244 sold.

Shares held by institutions64.4M

Sep '24Jun '26

Safety check

From SEC filings

Share count growthYearly rate, last 3 years

+0.9%

Cash runwayAt last year's cash burn

Cash flow positive

Debt to equityLatest balance sheet: debt compared with what owners have

0.9x · $4.4B debt

Shares outstandingLatest reported

65M

Why moderate risk

Losing money
1 offering filing in 6 months (may sell new shares)

Earnings reports

Last 12

Next reportAround Jan 11, 2027 (est.)Estimated from the same quarter last year

Results filedOct 26
Results filedAug 3
Results filedMay 5
Results filedFeb 24
Results filedJan 12

Flags and big holders

Offerings 6 months, flags 12 months, holders 90 days

Major agreementAug 31 · View filing ↗Offering New 5%+ holder (passive)Aug 6 · View filing ↗Big holder

Insider trades

Open-market buys and sells, last 90 days

Bought$00 insiders

Sold$1.9M2 insiders, 2 pre-planned

Insider	Trade	Shares	Avg price	Value	Owns after	Date
Renee D GalaPresident & CEO	Sell	2K	$236.40	$473K	141K	Oct 6Filing ↗
-1.4% of their holdings Pre-planned sale (10b5-1) Also Director Filed 1 day after
Bruce C CozaddDirector	Sell	6K	$230.33	$1.4M	346K	Oct 1Filing ↗
-1.7% of their holdings Pre-planned sale (10b5-1) Filed 4 days after